Phase 4 N=14 Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery
Retinal Detachment
Primary: Post Operative Pain Day 1 — 2.2; 1.0 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
Retinal Detachment · Vitreoretinopathy Proliferative
Primary: The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) — 6 Participants
Phase 2 N=296 Bevacizumab Against Recurrent Retinal Detachment
Retinal Detachment · Proliferative Vitreoretinopathy
Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants
N/A N=142 Ab Interno Gelatin Stent With Mitomycin C Using Targeted Supra-tenon's Placement
Glaucoma
Primary: Postoperative Intraocular Pressure Changes Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Nontargeted Placement. — 20; 15 Participants
Phase 1 N=40 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Intravitreal Bevacizumab Injection · Pars Plana Vitrectomy · Tractional Retinal Detachment
Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar
N/A N=34 Mesh Fixation and Closure of Peritoneum Following Laparoscopic Hernia Repair Using N-butyl Cyanoacrylate
Hernia, Inguinal
Primary: Number of Participants With Safe Fixation of Mesh and Closure of Peritoneum by Clinical Investigation During Hospital Stay and Telephone Interview at Six Weeks…
Phase 4 N=59 Use of Bevacizumab in Trabeculectomy Surgery
Glaucoma · Optic Neuropathy · Fibrosis
Primary: Intraocular Pressure — 13.9; 13.2 mm Hg — p=<0.05
Phase 3 N=46 Effects of Pneumatic Vitreolysis on Vitreomacular Traction
Vitreomacular Traction
Primary: Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy — 78; 9 percentage of eyes
N/A N=35 Effects of Pneumatic Vitreolysis on Macular Hole
Vitreomacular Traction (VMT) · Full-thickness Macular Holes (MH)
Primary: Proportion of Eyes With Macular Hole Closure of Inner Retinal Layers Without Rescue Vitrectomy — 10 Eyes
N/A N=12 Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus
Keratoconus
Primary: Number of Participants With Normal Vision — 8 Participants
Phase 3 N=130 Corneal Collagen Cross-Linking for Ectasia (CXL)
Ectasia
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -0.5; 0.5 diopters
N/A N=32 Phacoemulsification Versus Phacoemulsification With Micro-bypass Stent
Primary Angle-Closure Glaucoma · Primary Angle Closure Without Glaucoma Damage
Primary: Change in Intraocular Pressure Between Baseline and 1 Year — 15; 14.7 mmHg
N/A N=60 Augmented Medial Rectus Muscle Recession Versus Posterior Scleral Fixation in Partially Accommodative Esotropia
Partially Accommodative Esotropia
Primary: Success Rate — 12; 18 Participants — p=0.18
N/A N=448 Safety and Suitability of ICL for Correction of Refractive Errors Without the Use of Dispersive OVDs
Refractive Errors · Myopia · Myopic Astigmatism
Primary: Unaided Visual Acuity After the Procedure — 0.264; 0.227 LogMar vision
N/A N=372 Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)
Cataract
Primary: Percent Change in Mean Epithelial Cell Density (ECD) — -8.4; -6.8 percentage change in ECD
Phase 2 N=26 Pupil Dilation for Treatment of IFIS
Intraoperative Floppy Iris Syndrome
Primary: Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye — 6.76; 7.17 millimeters
Phase 2 N=124 PRM-151 in the Prevention of Scarring Following Trabeculectomy
Glaucoma
Primary: Safety of Subconjunctival Injection — 274; 220; 166; 113 Number of occurrences
N/A N=262 EYEFILL® C. -US Viscoelastic Clinical Investigation
Cataract
Primary: Mean Percent Cell Change (Preservation of Endothelium) — -10.05; -10.13 percent cell change
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
N/A N=37 Endothelial Bleb Response With Toric Lenses
Ametropia
Primary: Endothelial Bleb Areas on Cornea: Session A- Open Eye — 0.1; 2.0; 0.2; 2.1 Percent Difference of Bleb Area
N/A N=22 Efficacy of Scleral Contact Lenses for Daily Wear for Regular and Irregular Refractive Errors Compared to Habitually Worn Scleral Lenses
Scleral Lens Wearers
Primary: The Primary Endpoint of the Study is the Overall Satisfaction and Desire to Continue Wearing the Study Lenses — 15; 2; 4 Participants
N/A N=20 Optimizing the Ocular Surface Prior to Cataract Surgery
Corneal Dystrophy, Epithelial Basement Membrane
Primary: Change in Intraocular Lens Calculation — 1.56; 0.94 D
N/A N=390 A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50
Cataract
Primary: Percentage of Participants Who Experienced at Least One Intraocular Pressure (IOP) Measurement ≥30 Millimeters of Mercury (mmHg) at Any Post-Surgical Follow-up Visit…
Phase 4 N=30 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
Diabetic Macular Edema · Epiretinal Membrane
Primary: Central Retinal Thickness — 350 micrometers
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
N/A N=78 Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes
Idiopathic Macular Hole
Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters
N/A N=222 BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007
Prostate Cancer
Primary: Safety Endpoint: Number of Subjects in the Balloon and Control Groups With Rectal, Device or Procedure-related Grade > 1 AEs Within 6 Months of Procedure — 25; 18…
Phase 4 N=100 Subconjunctival Versus Direct Mitomycin C in Trabeculectomy
Open Angle Glaucoma
Primary: Percentage of Participants Achieving Intraocular Pressure Reduction Thresholds — 21; 21; 1; 3 Participants
Phase 4 N=20 Vault Evaluation After ICL Implantation
Nearsightedness
Primary: Mean Difference Between Predicted and Actual Central Vault at 1-month After ICL Implantation — 0.170 Milimeters
Phase 4 N=2 Tissue Sealant Use in LASIK Enhancement Surgery
Epithelial Ingrowth
Primary: Slit Lamp Examination for Presence of Epithelial Ingrowth Under LASIK Flap — 0 Eyes